1. Genetic Profiling in Inflammatory Bowel Disease: From Association to Bedside 
Johan van Limbergen, Dana Philpott, Anne M. Griffiths 
Gastroenterology 
Volume 141, Issue 5, Pages e1 (November 2011)
DOI: /j.gastro
Copyright © 2011 AGA Institute Terms and Conditions

2. Figure 1
Genetic risk profiling and patient stratification relies on our understanding of the complex interaction of genetic susceptibility factors with changing environmental factors, their influence on the intestinal microbiome and interactions with epigenetic factors, and microRNA-mediated regulation of gene expression.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2011 AGA Institute Terms and Conditions

3. Figure 2
NOD2-interacting proteins and the pathways they are involved in. RIPK2,30 Receptor-interacting serine-threonine kinase 2; Erbin,31 erbb2 interacting protein; ATG16L1,32 ATG16 autophagy related 16-like 1; Grim-19 (NDUFA13),33 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13; NLRC4,34 Nod-like receptor family CARD domain-containing protein 4; Caspase 1,35 apoptosis-related cysteine peptidase (interleukin 1, beta, convertase); HTATIP (KAT5),28 K(lysine) acetyltransferase 5; PPP2R5E,28 protein phosphatase 2, regulatory subunit B′, epsilon isoform (involved in cell growth/division); VIM,28 vimentin (involved in cytoskeleton/immune response); FIS1,28 fission 1 (mitochondrial outer membrane) homolog (S cerevisiae); GALNT2,28 UDP-N-acetyl-alpha-d-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2 (GalNAc-T2); TLE1,28 transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila); CARD9,36 caspase recruitment domain family, member 9; BID,37 BH3 interacting domain death agonist.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2011 AGA Institute Terms and Conditions